Adherence to treatment regimen and bleeding rates in a prospective cohort of youth and young adults on low-dose daily prophylaxis for severe hemophilia A

[1]  V. Blanchette,et al.  Pilot study of once‐a‐day prophylaxis for youth and young adults with severe haemophilia A , 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

[2]  V. Blanchette,et al.  Generic and disease-specific quality of life among youth and young men with Hemophilia in Canada , 2016, BMC Hematology.

[3]  T. Dutta,et al.  A randomized study of very low‐dose factor VIII prophylaxis in severe haemophilia – A success story from a resource limited country , 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

[4]  Y. T. van der Schouw,et al.  Discontinuing early prophylaxis in severe haemophilia leads to deterioration of joint status despite low bleeding rates , 2016, Thrombosis and Haemostasis.

[5]  C. Santoro,et al.  Benefits of prophylaxis versus on-demand treatment in adolescents and adults with severe haemophilia A: the POTTER study , 2015, Thrombosis and Haemostasis.

[6]  J. Oldenburg,et al.  Controlled, cross-sectional MRI evaluation of joint status in severe haemophilia A patients treated with prophylaxis vs. on demand , 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

[7]  S. Jackson,et al.  An objective method for assessing adherence to prophylaxis in adults with severe haemophilia , 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

[8]  T. Humphries,et al.  Consequences of switching from prophylactic treatment to on‐demand treatment in late teens and early adults with severe haemophilia A: the TEEN/TWEN study , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[9]  R. Ljung,et al.  Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s. , 2013, Blood.

[10]  J. Mahlangu,et al.  Guidelines for the management of hemophilia , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[11]  J. Astermark,et al.  Daily dosing prophylaxis for haemophilia: a randomized crossover pilot study evaluating feasibility and efficacy , 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

[12]  L. Valentino,et al.  A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management , 2012, Journal of thrombosis and haemostasis : JTH.

[13]  G. Spotts,et al.  Retrospective analysis of differences in annual factor VIII utilization among haemophilia A patients , 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

[14]  J. Epstein,et al.  The relative burden of haemophilia A and the impact of target joint development on health‐related quality of life: results from the ADVATE Post‐Authorization Safety Surveillance (PASS) study , 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

[15]  L. Mantovani,et al.  A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study) , 2011, Journal of thrombosis and haemostasis : JTH.

[16]  R. Engelbert,et al.  Validation of a new pediatric joint scoring system from the International Hemophilia Prophylaxis Study Group: Validity of the hemophilia joint health score , 2011, Arthritis care & research.

[17]  M. Morfini,et al.  Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia , 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

[18]  R. Wu,et al.  Low dose secondary prophylaxis reduces joint bleeding in severe and moderate haemophilic children: a pilot study in China , 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

[19]  L. Valentino,et al.  Factor VIII prophylaxis for adult patients with severe haemophilia A: results of a US survey of attitudes and practices , 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

[20]  J. Astermark,et al.  Break‐through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A , 2009, Journal of thrombosis and haemostasis : JTH.

[21]  H. M. van den Berg,et al.  A survey of adherence to haemophilia therapy in six European countries: results and recommendations , 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

[22]  P. Mannucci,et al.  Effects of secondary prophylaxis started in adolescent and adult haemophiliacs , 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

[23]  Alan R. Cohen,et al.  Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. , 2007, The New England journal of medicine.

[24]  E. Remor,et al.  Disease‐specific quality‐of‐life measurement tools for haemophilia patients , 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

[25]  M. Manco‐Johnson,et al.  Barriers to compliance with prophylaxis therapy in haemophilia , 2001, Haemophilia : the official journal of the World Federation of Hemophilia.

[26]  F. Beek,et al.  Long‐term outcome of individualized prophylactic treatment of children with severe haemophilia , 2001, British journal of haematology.

[27]  R. Ljung,et al.  Improved cost‐effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia A , 1997, Haemophilia : the official journal of the World Federation of Hemophilia.

[28]  H. Pettersson,et al.  Twenty‐five years' experience of prophylactic treatment in severe haemophilia A and B , 1992, Journal of internal medicine.